A prospective study of the impact of serial troponin measurements on the diagnosis of myocardial infarction and hospital and six-month mortality in patients admitted to ICU with non-cardiac diagnoses. by Ostermann, M et al.
Ostermann et al. Critical Care 2014, 18:R62
http://ccforum.com/content/18/2/R62RESEARCH Open AccessA prospective study of the impact of serial
troponin measurements on the diagnosis of
myocardial infarction and hospital and six-month
mortality in patients admitted to ICU with
non-cardiac diagnoses
Marlies Ostermann1, Jessica Lo2,3, Michael Toolan1, Emma Tuddenham4, Barnaby Sanderson1, Katie Lei1, John Smith1,
Anna Griffiths5, Ian Webb5, James Coutts5, John Chambers5, Paul Collinson6, Janet Peacock2,3, David Bennett1
and David Treacher1*Abstract
Introduction: Troponin T (cTnT) elevation is common in patients in the Intensive Care Unit (ICU) and
associated with morbidity and mortality. Our aim was to determine the epidemiology of raised cTnT levels
and contemporaneous electrocardiogram (ECG) changes suggesting myocardial infarction (MI) in ICU patients
admitted for non-cardiac reasons.
Methods: cTnT and ECGs were recorded daily during week 1 and on alternate days during week 2 until discharge
from ICU or death. ECGs were interpreted independently for the presence of ischaemic changes. Patients were
classified into four groups: (i) definite MI (cTnT ≥15 ng/L and contemporaneous changes of MI on ECG), (ii) possible
MI (cTnT ≥15 ng/L and contemporaneous ischaemic changes on ECG), (iii) troponin rise alone (cTnT ≥15 ng/L), or
(iv) normal. Medical notes were screened independently by two ICU clinicians for evidence that the clinical teams
had considered a cardiac event.
Results: Data from 144 patients were analysed (42% female; mean age 61.9 (SD 16.9)). A total of 121 patients (84%)
had at least one cTnT level ≥15 ng/L. A total of 20 patients (14%) had a definite MI, 27% had a possible MI, 43%
had a cTNT rise without contemporaneous ECG changes, and 16% had no cTNT rise. ICU, hospital and 180-day
mortality was significantly higher in patients with a definite or possible MI.
Only 20% of definite MIs were recognised by the clinical team. There was no significant difference in mortality
between recognised and non-recognised events.
At the time of cTNT rise, 100 patients (70%) were septic and 58% were on vasopressors. Patients who were septic
when cTNT was elevated had an ICU mortality of 28% compared to 9% in patients without sepsis. ICU mortality
of patients who were on vasopressors at the time of cTnT elevation was 37% compared to 1.7% in patients not on
vasopressors.
Conclusions: The majority of critically ill patients (84%) had a cTnT rise and 41% met criteria for a possible or
definite MI of whom only 20% were recognised clinically. Mortality up to 180 days was higher in patients with a
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Cardiac troponin (cTn) is a sensitive and specific marker
of myocardial injury and is firmly established in the diag-
nosis of myocardial infarction (MI) [1]. Troponin eleva-
tion is common in patients in the intensive care unit
(ICU) (12 to 85%) and associated with increased morbid-
ity, mortality and length of stay [2-7]. There are multiple
potential aetiologies of troponin rises, including cardiac
causes, such as acute coronary syndromes (ACS), MI,
heart failure and pericarditis/myocarditis, and non-cardiac
causes, such as sepsis, pulmonary disease, renal impair-
ment and intracranial events, but MI and sepsis are the
most important causes in this patient cohort [8,9].
There is evidence that the mechanism of troponin
release and the prognostic significance of an elevated
troponin level vary depending on the underlying cause.
In patients with severe sepsis, troponin release can occur
in the absence of flow-limiting coronary artery disease and
may be due to transient loss in membrane integrity with
subsequent troponin leakage or microvascular thrombotic
injury [4,10,11]. Ver Elst et al. performed post-mortem
examinations in patients with septic shock and found
similar non-specific changes in troponin positive and
troponin negative patients, including elongated myocar-
dial fibers and interstitial oedema but no evidence of MI
[12]. Other studies not restricted to sepsis showed that 36
to 71% of patients with elevated troponin levels had
ischaemic changes on electrocardiogram (ECG) [2,6,13,14],
which therefore defines them as MIs by the consensus
criteria [1].
In clinical practice, the diagnosis of MI in ICU patients
is complicated by the frequent absence of clinical symp-
toms, the presence of confounding comorbidities and
the difficulty of interpreting ECG changes and troponin
elevation in the context of critical illness. Two studies by
Lim et al., conducted at a single centre, found that MI,
as defined by raised troponin levels and contemporan-
eous ischaemic ECG changes, occurred in 26 to 36% of
ICU patients [2,14]. Hospital mortality in patients with
MI was 43%, compared to 27% in those with elevated
troponin only. More than half of the MIs diagnosed by
prospective screening were missed by the clinical team,
although the associated mortality was similar irrespect-
ive of whether the events were recognised or not (39%
vs. 35% ICU mortality and 50% vs. 35% hospital mortal-
ity, respectively, with non-significant P-values).
Our objectives were i) to repeat the study by Lim and
colleagues in consecutive patients admitted for non-
cardiac reasons to a mixed medical-surgical ICU in the
UK, ii) to determine the epidemiology and outcomes of
recognised and unrecognised myocardial events as diag-
nosed by expert cardiologists, and iii) to investigate the
association between troponin elevation and contempor-
aneous sepsis and vasopressor use.Material and methods
Patients
We conducted a prospective observational study in the
30-bed, level 3 multi-disciplinary adult ICU at the St
Thomas’ site of Guy’s & St Thomas’ Hospital, a large ter-
tiary referral centre in London, UK. The ICU is a closed
ICU led by full time Intensive Care consultants. During
a seven-month period between June and December
2010, consecutive adult patients (age ≥18 years) were
recruited. Patients with a high probability of cardiac in-
jury or a primary cardiac diagnosis at ICU admission
were excluded, specifically those with a clinical diagnosis
of MI or out-of-hospital cardiac arrest, patients who
were post-cardiac surgery or cardiac intervention and
patients admitted following thoracic trauma with a high
likelihood of myocardial injury. Patients were also ex-
cluded if they had been transferred from an external
ICU following >24 hours stay, had previously been ad-
mitted to the ICU during their current hospital stay or
were expected to remain in ICU for <48 hours.
Sample collection
During the first week, we measured troponin T and rou-
tine blood tests and performed an ECG on a daily basis.
During the second week, troponin T and ECGs were
taken on alternate days until discharge from ICU, death
or for up to two weeks from admission, whichever oc-
curred first. Serial ECGs taken for research purposes
were stored in a secure locker in the research office.
Neither the troponin results nor the ECGs were available
to the clinical team caring for the patient. However, the
clinical team was allowed to perform ECGs and troponin
measurements separately as clinically indicated.
Data collection
At enrolment, baseline demographic data (age, gender,
ethnicity), known cardiovascular risk factors (ischaemic
heart disease (IHD), diabetes, hypertension, any other
type of vascular disease), Acute Physiology and Chronic
Health Evaluation (APACHE) II score, and admission
diagnosis were recorded.
We recorded use of vasopressors and the presence of
sepsis (defined as the presence of ≥2 criteria of systemic
inflammatory response syndrome (SIRS) and confirmed
or suspected diagnosis of infection) at baseline and daily
throughout the study period.
Laboratory analyses
Blood samples for troponin analysis were stored at -70°C
until batch analysis in the biochemistry laboratory at St
George’s University Hospital, London. Troponin T was
measured using the Roche electrochemiluminescent high
sensitivity sandwich immunoassay on the Elecsys 2010
(Roche Diagnostics, Indianapolis, IN, USA). The quoted
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variations are 1.5 to 3.4% (measured between 0.024 to
2.665 μg/L) and reference range is less than 15 ng/L
(99th percentile) [15]. Other laboratory tests were under-
taken at Guy’s & St Thomas’ Hospital.
Interpretation of troponin levels and diagnosis of
myocardial events
Troponin T levels were interpreted as raised if ≥15 ng/L,
corresponding to the 99th population percentile [1]. Ser-
ial ECGs were analysed independently by two senior car-
diologists (JCo, IW) at study completion and evaluated
for the presence of ischaemic changes consistent with an
acute MI using pre-defined criteria. In case of dis-
crepancy, adjudication was undertaken by a third senior
cardiologist (JCh). All cardiologists were blinded to the
troponin results and clinical details of the patients.
The diagnosis of an acute myocardial event was based
on the presence of elevated troponin T ≥15 ng/L and
contemporaneous ischaemic ECG changes according to
the European Society of Cardiology/American College of
Cardiology Committee criteria [1]. Patients were clas-
sified into four groups: (i) definite MI, with troponin
T ≥15 ng/L and contemporaneous ECG changes con-
sistent with MI, (ii) possible MI, with troponin T ≥15 ng/L
and contemporaneous ischaemic changes on ECG but not
fulfilling criteria for definite MI, (iii) troponin T rise alone,
and (iv) normal, with troponin T <15 ng/L and not falling
into the other three groups.
Medical notes were retrospectively reviewed independ-
ently by two ICU clinicians (DT, MO) for evidence that
the clinical team had considered the possibility of an
acute cardiac event based on ECG and/or troponin
criteria performed for clinical reasons and/or explicit
entries in the medical notes. Based on these results,
we distinguished between clinically recognised and unrec-
ognised acute myocardial events.
Outcomes
All patients were followed up for 180 days. The main out-
comes were mortality at discharge from ICU and hospital
and at 180 days, and length of stay in ICU and hospital.
In addition, we compared the outcomes of patients with
clinically recognised and unrecognised cardiac events.
Ethics
The study was approved by the Research Ethics Com-
mittee (REC) at St Thomas’ Hospital. If a patient had
the capacity, written informed consent was obtained
from the patient prior to enrolment. If a patient did not
have the capacity to consent as a result of the underlying
critical illness or sedating medication, the opinion of
a personal consultee was sought in accordance with
Section 32 of the Mental Capacity Act 2005 (UK). Inall cases, a personal consultee was someone with a
close personal relationship whom the person who
lacked capacity would trust with important decisions
about their welfare, for example, a spouse or partner,
adult child, parent or a close friend. The personal
consultee was asked to consider whether the person
who lacked capacity would be content to take part or
whether doing so might upset them, and to give their
opinion on what the past and present wishes and feelings
the person who lacked capacity would have been about
taking part in the study. In cases where a personal consultee
was consulted, patients were asked to give informed consent
retrospectively once they regained capacity. If retrospective
consent was declined, all collected samples and ECGs were
discarded. The REC waived the need for any additional
consent in case retrospective consent could not be obtained
due to death or lack of capacity. The REC felt it appropriate
that these patients were included in the analysis.
Statistics
Mean and standard deviation are reported for conti-
nuous data. Median and inter-quartile range (IQR) are
reported for skewed data such as length of stay. Binary
data are reported as frequency and percentage values.
Pairwise comparisons were made among three groups:
MI (combining the definite MI and possible MI groups),
elevated troponin T only, and normal (that is, no troponin
elevation). For baseline data, the t-test or the Mann-
Whitney U test were used as appropriate to analyse
continuous data; Pearson’s Chi-square or Fisher’s Exact
Test were used as appropriate in case of categorical vari-
ables. The Bonferroni method was used where there was
multiple significance testing: a P-value of less than 0.016
(0.05/n, where n is the number of tests) was considered
statistically significant. Multivariable regression was used
to examine the relationships among raised troponin, MI
and patient outcome after adjusting for imbalances in
baseline factors. Principal component analysis was used to
reduce the number of covariates because the sample is
small. Similarly, multivariable regression was used to
examine the difference on patient outcome between
clinically recognised and unrecognised cardiac events. All
analyses were done using Stata v.12 (StataCorp, College
Station, Texas, USA).
Results
Patient population
Over a seven-month period, 165 eligible patients were
identified and approached. In 16 cases, the patient or
personal consultee declined consent or assent. The
remaining 149 patients were enrolled in the study; how-
ever, 5 of these patients were excluded from the final
analysis. Reasons for exclusion were the presence of ACS
on admission to ICU which had not been recognised by
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in another hospital for advanced liver and neurosurgical
care within 48 hours of admission (n = 2).
The mean age of the remaining 144 patients was 61.9
(SD = 16.9); 42.4% were female (Table 1). The mean
APACHE II score at admission was 19.4 (SD = 6.2).
Acute renal replacement therapy was initiated in 48Table 1 Demographics and baseline data
Total
(n = 144)
Definite MI
(n = 20)
Possible MI
(n = 39)
Elevated cT
(n = 62)
Age, mean (SD) 61.9 (16.9) 62.3 (14.1) 67.6 (15.6) 64.3 (15.2)
Female, n (%) 61 (42%) 8 (40%) 16 (42%) 30 (48%)
White ethnicity, n (%) 123 (85.4%) 17 (85%) 34 (87%) 54 (87%)
APACHE II score,
mean (SD)
19.4 (6.23) 18.8 (5.47) 20.5 (5.84) 21.2 (5.84)
Past medical history
Ischaemic heart
disease, n (%)
24 (16.7%) 5 (25%) 8 (21%) 10 (16%)
Hypertension, n (%) 52 (36.1%) 8 (40%) 23 (59%) 19 (31%)
Diabetes, n (%) 41 (28.5%) 8 (40%) 14 (36%) 18 (29%)
Any type of vascular
disease, n (%)
29 (20.1%) 4 (20%) 12 (32%) 12 (19%)
APACHE, Acute Physiology and Chronic Health Evaluation; cTnT , cardiac troponin Tpatients (32%). The remaining 101 patients had a me-
dian serum creatinine 74 μmol/L (range 22 to 345).
Prevalence of troponin rise
The majority of patients (121 patients (84%)) had at least
one elevated troponin T result (cTnT ≥15 ng/L). Of these,
20 (14%) had contemporaneous ECG changes consistentnT only Normal (No cTnT elevation)
(n = 23)
P-value
45.4 (16.6) MI (definite or possible)
vs elevated cTnT; <0.001
MI (definite or possible)
vs normal: <0.001
Elevated cTnT vs normal: <0.001
7 (30.4%) MI (definite or possible)
vs elevated cTnT; 0.39
MI (definite or possible)
vs normal: 0.39
Elevated cTnT vs normal: 0.14
18 (78.3%) MI (definite or possible)
vs elevated cTnT; 0.92
MI (definite or possible)
vs normal: 0.36
Elevated cTnT vs normal: 0.32
13.2 (4.60) MI (definite or possible)
vs elevated cTnT; 0.20
MI (definite or possible)
vs normal: <0.001
Elevated cTnT vs normal: <0.001
1 (4.35%) MI (definite or possible)
vs elevated cTnT; 0.41
MI (definite or possible)
vs normal: 0.099
Elevated cTnT vs normal: 0.28
2 (9%) MI (definite or possible)
vs elevated cTnT; 0.014
MI (definite or possible)
vs normal: <0.001
Elevated cTnT vs normal: 0.048
1 (4%) MI (definite or possible)
vs elevated cTnT; 0.34
MI (definite or possible)
vs normal: 0.002
Elevated cTnT vs normal: 0.018
1 (4%) MI (definite or possible)
vs elevated cTnT; 0.31
MI (definite or possible)
vs normal: 0.031
Elevated cTnT vs normal: 0.17
; MI, myocardial infarction; SD, standard deviation.
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with a possible MI and 62 (43%) had elevated troponin
levels without contemporaneous ischaemic ECG changes.
The mean, median and maximum recorded troponin
levels are shown in Table 2.
Of the 121 patients with at least one troponin T
measurement ≥15 ng/L, 66 (46%) were in the range
15 to 100 ng/L, while 55 patients (38%) had at least one
measurement >100 ng/L, 24 patients (20%) had at least
one normal troponin measurement during study follow-
up and only 7 (5.8%) had a normal troponin on admission
to ICU. None of the patients with definite MI had a
normal troponin on ICU admission.
Patients with raised troponin levels were older (mean
age 65.8 versus 45.4, P <0.001) and had higher severity
of illness scores on admission to ICU (mean APACHE II
score 20.6 versus 13.2, P <0.001) than those without.
Hypertension, vascular disease and diabetes were signifi-
cantly more common in patients with elevated troponin
levels compared to those without a troponin rise but
there was no significant difference in the prevalence of
IHD (Table 1).
Outcomes
Patients who had an elevated troponin on admission to
ICU had a significantly higher ICU and hospital mortality
compared to those without (27% versus 3.3%, P = 0.003,
and 36% versus 3.3%, P <0.001, respectively). Patients with
a possible or definite MI during their stay in ICU had a
higher ICU, hospital and 180-day mortality compared to
those with elevated troponin levels without contempo-
raneous ischaemic ECG changes; however, the differences
were statistically not significant (Table 3).
There was no statistically significant difference in
length of stay in ICU and hospital between the different
troponin cohorts (Table 3).
Comparison between clinically recognised and
unrecognised myocardial events
Only 12 (20%) of the 59 study-identified definite and
possible MIs were suspected by the clinical team caringTable 2 Summary of troponin T levels in all patients over the
Troponin T levels (ng/L)
Group N Mean (SD)* Median*
Definite MI 20 214 (306) 73
Possible MI 39 229 (416) 63
Elevated troponin T only 62 97 (138) 55
Normal 23 3.3 (3.5) 2.4
ALL 144 133 (271) 45
MI, myocardial infarction; SD, standard deviation.
*Mean and median are of the patients’ mean troponin levels across follow-up perio
patients’ average troponin levels across follow-up period and are not used in the anfor the patient (Table 4). There was no significant dif-
ference in mortality between clinically recognised and
unrecognised MIs, although the number of clinically
recognised events was small. Length of ICU and hospital
stay were longer in those with a recognised MI com-
pared to patients who had an MI which remained unrec-
ognised (median of 17 versus 7 days for ICU stay, and
51 versus 18 days for hospital stay); the differences were
still significant after adjustment for baseline risk factors
(P = 0.024 and P = 0.030, respectively).
Of the 12 patients with a clinically recognised MI, all
had their troponin measured by the clinical team. Treat-
ment for an ACS was started in three patients, echocar-
diography was performed in three, two were referred to
cardiology for coronary angiography and one patient
was started on a glyceryl trinitrate infusion.
Association with sepsis and vasopressor use
On the first day in ICU, 105 patients (73%) satisfied ≥2
criteria for SIRS. During their stay in ICU, 104 (72%)
patients were septic. The diagnosis of sepsis was associ-
ated with increased ICU mortality (28% versus 8%) and
increased hospital mortality (35% versus 15%).
Treatment with one or more inotropic or vasoactive
drug was necessary in 86 patients of whom 98% received
norepinephrine and 6 patients were on two or more
medications. Use of vasoactive drugs was associated with
both ICU and hospital mortality (37% versus 2%, and
44% versus 7%, respectively).
On the day of troponin rise, 100 patients (69%) had
sepsis. Their ICU mortality was 28% compared to 9% in
patients who were not septic when they had an elevated
troponin level. On the day of troponin elevation, 84
patients (58%) were receiving vasopressors. Their ICU
mortality was 37% compared to 2% in patients who were
not on vasopressors.
Among patients with a possible or definite MI, 68% of
patients were septic and 63% were on vasopressors on
the day when the criteria for MI were fulfilled, with
similar proportions in those with a definite and possible
MI. Only 30% of patients who never had a troponin risewhole study period
Minimum of all observations
across all days
Maximum of all observations
across all days
9 3,093
5 3,335
0 1,337
0 14
0 3,335
d in each group. (Note that this summary of data serves to illustrate the
alyses of patient outcomes).
Table 3 Outcome according to MI category
Total MI (definite or
possible MI)
Elevated
cTnT only
No cTnT rise
(normal)
unadjusted P-value adjusted P-value*
(n = 144) (n = 59) (n = 62) (n = 23)
ICU mortality, n (%) 32 (22%) 17 (29%) 14 (23%) 1 (4.35%) MI vs elevated cTnT; 0.43 0.32
MI vs normal: 0.04 0.16
Elevated cTnT vs
normal
0.081 0.30
Hospital mortality,
n (%)
42 (29%) 22 (37%) 19 (31%) 1 (4%) MI vs elevated cTnT 0.44 0.39
MI vs normal 0.015 0.070
Elevated cTnT vs
normal
0.032 0.14
180 days mortality,
n (%)
51 (35%) 27 (46%) 23 (37%) 1 (4%) MI vs elevated cTnT 0.33 0.28
MI vs normal 0.006 0.058
Elevated cTnT vs normal 0.015 0.13
ICU length of stay,
median (IQR)
7 (3 to 12) 8 (3 to 18) 6 (3 to 11) 4 (2 to 10) MI vs elevated cTnT 0.13 0.13
MI vs normal 0.07 0.058
Elevated cTnT vs normal** 0.48 0.36
Hospital length of stay,
median (IQR)
22 (10 to 46) 30 (12 to 51) 19.5 (9 to 46) 18 (5 to 38) MI vs elevated cTnT 0.27 0.42
MI vs normal 0.17 0.16
Elevated cTnT vs normal** 0.57 0.37
cTnT, cardiac troponin T; ICU, intensive care unit; IQR, inter-quartile range; MI, myocardial infarction.
*adjusted for age, APACHE II score, hypertension, diabetes and any type of vascular disease (reduced to two principal components in the regression models).
**estimates based on log-transformed outcomes.
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their stay in ICU.
Discussion
This study confirms that raised troponin levels are
very common among critically ill patients admitted to
ICU for non-cardiac reasons and are associated with
an increased mortality up to 180 days. The large ma-
jority of ICU patients (84%) had one or more elevated
troponin values and 41% met the criteria for MI.
Only 20% of definite MIs were recognised by the
clinical team.Table 4 Comparison between cardiac events recognised by cl
Recognised MI
(definite or possible MI) (n = 12)
ICU mortality, n (%) 2 (17%)
Hospital mortality, n (%) 3 (25%)
180 days mortality, n (%) 5 (42%)
ICU length of stay, median (IQR) 14.5 (8.5 to 20)
Hospital length of stay, median (IQR) 48.5 (35.5 to 63.5)
ICU, intensive care unit; IQR, inter-quartile range; MI, myocardial infarction.
*P-value from unadjusted regression model where group was recognised and not r
**P-value from adjusted regression model where group was recognised and not rec
and any type of vascular disease (reduced to two principal components in regressio
***estimates based on log transformed outcome.Previous studies have reported a wide range in preva-
lence of troponin elevation in critically patients. A meta-
analysis by Lim et al. showed that in 20 studies, elevated
troponin was found in a median of 43% (IQR 21% to 59%)
of 3,278 patients [3]. Prevalences of 51 to 62% were
reported in three studies [7,14,15]. However, these studies
used a variety of different assays, thresholds to define
elevation and measurement frequencies, and patient
groups varied, making direct comparison impossible.
Both Reynolds et al. and Audimooolam et al. used a
troponin I assay with a cut-off at or near the 99th percentile
whereas Lim et al. used troponin T at a cut-off higherinical teams and unrecognised events
Not recognised MI
(definite or possible MI) (n = 47)
unadjusted
P-value*
adjusted
P-value**
15 (32%) 0.31 0.22
19 (40%) 0.33 0.24
22 (47%) 0.75 0.52
7 (3 to 14) 0.030*** 0.024***
24 (11 to 42) 0.038*** 0.030***
ecognised.
ognised; adjusted variables were age, APACHE II score, hypertension, diabetes
n models).
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nin T is more frequently elevated at the 99th percentile
than troponin I in critically ill patients, potentially due to
renal dysfunction [17].
The exact prevalence of real myocardial infarction in
critically ill patients is also not known. Lim and colleagues
found that 25.8% of all patients in a single mixed medical-
surgery ICU had an MI when assessed by clinically-
indicated investigations but prevalence was higher at 36%
when using protocol-driven screening investigations [2,14].
A study of 26 septic surgical ICU patients reported a 26.9%
prevalence of ischaemic ECG and troponin elevation and
a further 7.7% with indeterminate ECG changes [18]. Our
study in selected patients who were admitted for non-
cardiac reasons revealed a 41% prevalence of possible and
definite MIs.
One notable finding of our study, which mirrors that
of Lim et al. and others [14,19], is that only 20% of
study-diagnosed MIs were recognised by the clinical
team and mortality was no different between recognised
and unrecognised events. Diagnosing an MI in critically
ill patients is not straightforward. There are no specific
guidelines on the interpretation of ECG changes during
critical illness and the reliability of ECG interpretation
in critically ill patients for the detection of myocardial
ischemia is uncertain. Similarly, there are no separate
guidelines for patients with renal impairment. The most
recent expert consensus guideline for the Universal Defin-
ition of Myocardial Infarction acknowledges that “it is
often a challenge for the clinician, caring for a critically ill
patient with severe single organ or multi-organ pathology,
to decide on a plan of action when the patient has elevated
cardiac troponin values” [1].
Relatively little research has focused on the patterns of
ECG changes and their interpretation. Lim et al. estab-
lished that there was only modest agreement between
different operators interpreting the same ECG when they
were not provided with other contextual information
(troponin measurements, clinical history) [20]. Mehta et
al. performed a study in 121 patients with sepsis and
asked two independent assessors to analyse the ECGs
without knowledge of troponin levels [21]. Inter-rater
agreement for ischaemia was fair but improved when
the troponin results were revealed to them. To our best
knowledge, there are no published studies correlating
infarct-characterising ECG changes in ICU patients with
angiography-proven coronary artery disease. The prob-
lem is confounded further by the fact that critically ill
patients can display classic ST elevation in the absence
of a troponin elevation, for instance, in the context of
intracranial haemorrhage [22].
Ammann et al. demonstrated, with echocardiography or
autopsy as appropriate, that 70% of patients with troponin
elevation did not have significant coronary artery disease[23]. However, documented IHD (that is, previously known
and recorded at admission) is common in ICU patients in
general, as it was in our study group [24].
Several previous papers confirmed that troponin ele-
vation is associated with increased ICU and hospital
mortality in critically ill patients [3,5,23,25-29]. Our data
demonstrate that the increased risk of dying persists
even after discharge from hospital up to at least 180 days
with no statistically significant difference between pos-
sible and definite MIs. Several potential mechanisms
might explain troponin release in critically ill patients.
These include demand ischaemia with or without a
degree of coronary vasospasm, the effects of catechol-
amines and sepsis on the myocardium causing membrane
leak and microscopic circulatory thrombosis or maldis-
tribution. We noted that patients with MI had higher me-
dian and maximum troponin levels than those with
troponin elevations alone without contemporaneous ECG
changes. Mortality was low in patients who had normal
troponin measurements throughout their ICU admission.
We also found that significantly more patients with a possible
or definite MI were receiving vaso-active drugs at the time of
elevated troponin levels compared to patients who did not
have a troponin rise. These findings support the hypothesis
that a proportion of patients with a troponin rise may indeed
have suffered from critical coronary artery disease and the
acute illness, sepsis and/or treatment with catecholamines
may have acted as a “stress test” and identified a cohort of pa-
tients with a very high risk of dying in six months.
The strengths of this study include the selection of
patients who were admitted for non-cardiac reasons and
the ECG interpretation by two senior cardiologists with
adjudication by a third cardiologist in case of disagree-
ment. Patients were also followed for 180 days which is
longer than in previous studies.
It is important to acknowledge some limitations, too.
Firstly, we conducted a single centre study. Although we
enrolled more patients than the majority of previous
studies, we were limited in our subgroup analyses by
patient numbers. Our recording of smoking history was
incomplete, and we did not collect any information on
the use of cardio-protective medication. Finally, we were
unable to perform Kaplan-Meier analyses and do not
know the exact causes of death.
Clinical implications and future work
In view of the important association between troponin
elevation and mortality in patients admitted to ICU
without a primary cardiac diagnosis, and the high num-
ber of myocardial events which were not recognised by
the clinical team, more work is necessary to improve the
understanding of the aetiology of troponin increases. It
is also necessary to explore whether there is a role for
screening and targeted interventions. Although cardio-
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raphy and percutaneous intervention) have a clear role in
the patient with ACS outside of the ICU, their role in
critically ill patients with a raised troponin is still unclear.
Many ICU clinicians do not routinely perform either
troponin measurement or regular ECGs in patients with-
out a cardiac diagnosis on admission. Our results show
that daily troponin measurement in conjunction with
regular ECGs may identify patients at high short- and
longer-term risk in whom medical treatment according to
an ACS protocol and appropriate diagnostic work-up may
be beneficial.Conclusions
Myocardial infarction is common amongst critically ill
patients, is poorly diagnosed and associated with sig-
nificant short- and long-term mortality. Further research
is warranted to characterise better the underlying aeti-
ology of the troponin rise in critically ill patients and
to assess the impact of routine screening and targeted
interventions.Key messages
 Myocardial infarction is common in critically ill
patients but poorly recognized in clinical practice.
 Myocardial infarction during critical illness is
associated with a significantly increased risk of
dying in up to 180 days.
 More work is necessary to evaluate the benefit of
routine screening for myocardial infarction and the
benefit of targeted interventions.
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